Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;57(2):308-315.
doi: 10.1080/10826084.2021.2012484. Epub 2021 Dec 10.

The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice

Shashi N Kapadia  1   2 , Judith L Griffin  1   3 , Justine Waldman  3 , Nicolas R Ziebarth  4 , Bruce R Schackman  2 , Czarina N Behrends  2
Affiliations

The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice

Shashi N Kapadia et al. Subst Use Misuse. 2022.

Abstract

Background: To respond to the U.S. opioid crisis, new models of healthcare delivery for opioid use disorder treatment are essential. We used a qualitative approach to describe the implementation of a low-threshold buprenorphine treatment program in an independent, community-based medical practice in Ithaca, NY.

Methods: We conducted 17 semi-structured interviews with program staff, leadership, and external stakeholders. Then we analyzed these data using content analysis. We used purposeful sampling aiming for variation in job title for program staff, and in organizational affiliation for external stakeholders.

Results: We found that opening an independent medical practice allowed for low-threshold buprenorphine treatment with less regulatory oversight, but state-certification was ultimately required to ensure financial sustainability. Relying on health insurance reimbursement alone led to funding shortfalls and additional funding sources were also required. The practice's ability to build relationships with licensed substance use treatment programs, community organizations, the legal system, and government agencies in the region differed depending on how much these entities supported a harm reduction philosophy compared to abstinence-based treatment. Finally, expanding the practice to a second location in a different region, co-located with a syringe service program, required adapting to a new cultural and political environment.

Conclusion: The results from this study provide insight about the challenges that independent medical practices might face in delivering low-threshold buprenorphine treatment. They support policy efforts to address the financial burdens associated with providing low-threshold buprenorphine therapy and inform the external relationships that other providers would need to consider when delivering novel treatment models.

Keywords: Low threshold; buprenorphine; co-located; harm reduction; integrated care; qualitative; stakeholders.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Kapadia has received research grants paid to his institution from Gilead Sciences Inc, unrelated to the current study, for research related to hepatitis C. All other authors declare no conflicts of interest.

References

    1. Andrews CM, Abraham AJ, Grogan CM, Westlake MA, Pollack HA, & Friedmann PD (2019). Impact of medicaid restrictions on availability of buprenorphine in addiction treatment programs. American Journal of Public Health, 109(3), 434–436. 10.2105/AJPH.2018.304856 - DOI - PMC - PubMed
    1. Andrilla CHA, Coulthard C, & Larson EH (2017). Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Annals of Family Medicine, 15(4), 359–362. 10.1370/afm.2099 - DOI - PMC - PubMed
    1. Andrilla CHA, Moore TE, Patterson DG, & Larson EH (2019). Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update. The Journal of Rural Health, 35(1), 108–112. 10.1111/jrh.12307 - DOI - PubMed
    1. Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, & Barclay D (2018). Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse, 39(2), 167–172. 10.1080/08897077.2018.1443541 - DOI - PMC - PubMed
    1. Barocas JA, & Saitz R (2019). Being explicit about decisions: prescribe medications for opioid use disorder on the basis of proven effectiveness, not beliefs. Annals of Internal Medicine, 170(2), 127–128. 10.7326/M18-3293 - DOI - PubMed

Publication types